Wendy Weinstein, MD
Psychiatry · Buffalo, NYNPI 1679523484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $323,718 of the $387,693 with a category attached, or 83.5%. 32 manufacturers reported payments, led by AbbVie at 36.7% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,507 payments — averaging $257.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$142K
- Otsuka America Pharmaceutical, Inc.$126K
- Vanda Pharmaceuticals Inc.$61K
- Sunovion Pharmaceuticals Inc.$10K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$9K
- E.r. Squibb & Sons, L.L.C.$9K
- plus $31K from 26 others
What the payments were for
- Consulting fees$7,5322%
- Speaking & faculty fees$323,71883%
- Travel & lodging$30,7418%
- Food & beverage$25,5117%
- Education$1910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 369 | $142,182 |
| Otsuka America Pharmaceutical, Inc. | 246 | $126,350 |
| Vanda Pharmaceuticals Inc. | 128 | $60,798 |
| Sunovion Pharmaceuticals Inc. | 196 | $9,568 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 108 | $9,465 |
| E.r. Squibb & Sons, L.L.C. | 20 | $8,601 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $8,092 |
| Johnson & Johnson | 28 | $7,953 |
| Idorsia Pharmaceuticals US Inc | 30 | $7,924 |
| Alkermes, Inc. | 46 | $1,671 |
| Neurocrine Biosciences, Inc. | 51 | $1,243 |
| Lundbeck LLC | 113 | $1,160 |
| Teva Pharmaceuticals USA, Inc. | 38 | $851 |
| Axsome Therapeutics, Inc. | 12 | $303 |
| Corium, LLC | 19 | $284 |
| Eisai Inc. | 9 | $245 |
| Jazz Pharmaceuticals Inc. | 8 | $164 |
| Janssen Scientific Affairs, LLC | 1 | $131 |
| Supernus Pharmaceuticals, Inc. | 5 | $128 |
| Neos Therapeutics, LP | 7 | $93 |
| Indivior Inc. | 1 | $79 |
| Avanir Pharmaceuticals, Inc. | 4 | $67 |
| Neuronetics, Inc. | 1 | $56 |
| Biogen | 3 | $53 |
| Bausch Health US, LLC | 3 | $41 |
| Ironshore Pharmaceuticals Inc. | 3 | $37 |
| Arbor Pharmaceuticals, Inc. | 3 | $36 |
| Shire North American Group Inc | 2 | $34 |
| Alfasigma USA, Inc. | 2 | $31 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$137,866
- REXULTI$123,403
- Fanapt$59,150
- CAPLYTA$8,062
- QUVIVIQ$7,596
- TRINTELLIX$7,545
- SPRAVATO$7,232
- LATUDA$6,836
- COBENFY$5,633
- ARISTADA$1,500
- LYBALVI$1,355
- INGREZZA$455
- ARISTADA INITIO$375
- VIIBRYD$200
- INVEGA SUSTENNA$131
- AUSTEDO$125
- Dayvigo$125
- Austedo XR$125
- Auvelity$111
How this compares
$387,693 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 171 | $252,991 |
| RexultiBrexpiprazole | 155 | $245,855 |
| TrintellixVortioxetine Hydrobromide | 92 | $64,627 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $36,223 |
| Lurasidone Hcl | 64 | $17,793 |
| FetzimaLevomilnacipran Hcl | 21 | $16,016 |
| SeroquelQuetiapine Fumarate | 12 | $14,033 |
| Duloxetine Hcl | 461 | $11,321 |
| Bupropion XlBupropion Hcl | 494 | $9,245 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 203 | $8,056 |
| Lisdexamfetamine Dimesylate | 24 | $5,717 |
| Aripiprazole | 231 | $5,592 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 206 | $4,285 |
| Clonazepam | 417 | $4,257 |
| Alprazolam | 326 | $3,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $142,182 | $269,007192 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $126,350 | $245,855155 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $8,092 | $64,62792 claims |
| Alkermes, Inc.Lybalvi | $1,671 | $36,22324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Buffalo
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.